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esistance to
ntiplatelet Resistance*
s it Justified?
teven R. Steinhubl, MD, FACC,
ichard Charnigo, PHD,
avid J. Moliterno, MD, FACC
exington, Kentucky
t is unusual for a month to go by without a new antiplatelet
resistance” or “non-responder” article appearing in the
ardiology literature. Considering the fact that antiplatelet
herapies, primarily aspirin, have been around for more than
century and variability in response to some degree has been
ecognized for nearly 40 years (1), why is there now so much
ress interest? First, and most importantly, it is because
therosclerotic vascular disease remains the leading killer in
he industrialized world today and antiplatelet therapy is
till one of the most effective therapies for its treatment. For
xample, in the setting of an ST-segment elevation myo-
ardial infarction, the 23% relative reduction in short-term
ortality provided by an aspirin tablet (2) rivals the 27%
ortality reduction achieved with primary angioplasty over
brinolytic therapy (3).
See pages 1748 and 1753
Second, an acceptable alternative to aspirin, clopidogrel,
ecently has become widely available. Before this, the only
lternatives to aspirin for chronic antithrombotic therapy
ere warfarin and ticlopidine, and there are several reasons
hat made each an inferior alternative. Therefore, for the
rst time we have a long-term antiplatelet treatment option
hat could make measuring a response to aspirin clinically
orthwhile. Third, the medical relevance of antiplatelet
esponsiveness has tremendous implications because of the
heer number of people that are affected. It is estimated that
n the U.S. alone roughly 30 million individuals take an
spirin daily for cardioprotection. Even as a newcomer,
lopidogrel already has been prescribed to more than 20
illion patients worldwide.
A final reason antiplatelet responsiveness has so much
ecent interest is because of our improved understanding of
latelet biology and newfound appreciation that there are
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, the Gill Heart Institute, and the
epartment of Statistics, the University of Kentucky, Lexington, Kentucky. Dr.
teinhubl has served as a consultant for and received research support fromh
ccumetrics Inc., the maker of the Ultegra Rapid Platelet Function Assay, and the
ristol-Myers Squibb/Sanofi-Aventis partnership, makers of clopidogrel.ultiple genetic and environmental influences on platelet
esponsiveness. These multiple influences, not only on the
latelet itself, but also on the absorption and metabolism of
ntiplatelet agents, render the assumption that one dose of
n antiplatelet medication would yield the maximal clinical
enefit in all patients about as tenable as assuming that one
ose of hydrochlorothiazide would yield the same benefit in
ll hypertensive patients.
With the heightened interest and study of antiplatelet
esponsiveness, one would hope there has been clear head-
ay in addressing several key issues. For instance, what
ercentage of cardiac patients “inadequately” responds to
spirin? Unfortunately, there is no certain answer. On the
asis of trials that have correlated some change in platelet
unction among aspirin-treated patients with clinical out-
omes, the reported prevalence ranges from 5% to 75%
4,5), a range too wide to be useful. Along these lines, it also
emains unknown whether response to antiplatelet therapy
s more binary or continuous. That is, can an individual
eally have an all-or-none response? Like other biologic
rocesses under polygenetic and environmental control, it
eems more plausible that platelet responsiveness is contin-
ous. Indeed, a normally distributed platelet response to
lopidogrel was reported among 544 individuals (6). The
atural question therefore is what level of response to
ntiplatelet therapy along this continuum places a patient at
ncreased risk for thrombosis or for bleeding events?
An underappreciated unknown—especially considering
he many studies using different methods for measuring
latelet response to therapy—is whether there is a single
est way to measure platelet function and to define the lack
f adequate suppression by antiplatelet therapies. Light
ransmittance platelet aggregometry generally is considered
he gold standard for determining platelet function, but the
rtificial nature of the test makes its relevance to in vivo
latelet function questionable, and the technical demands of
he method make it somewhat impractical. In addition,
ggregation is but one of several important platelet func-
ions. Nonetheless, one clinical study has correlated light
ransmittance aggregometry results in patients treated with
spirin with clinical outcomes (5). Urinary thromboxane
etabolite levels also have been found to be associated with
linical outcomes (4); however, other factors aside from
spirin influence thromboxane metabolite levels, including
he degree of atherosclerosis (7) and inflammatory diseases
8). Multiple point-of-care devices have been developed and
ay be the key to widespread clinical use of platelet function
esting. Some assays have been shown to provide predictive
alue (i.e., correlate with clinical outcomes) (9), whereas
thers have not (10).
Even more fundamental, however, a limitation to nearly
ll studies attempting to correlate aspirin “responsiveness”
nd clinical outcomes is that they have not truly measured
he independent effects of aspirin. Rather, platelet function
as been most commonly measured among patients already
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Editorial Comment June 7, 2005:1757–8aking aspirin. Therefore, what is really being measured is
he patient’s responsiveness to aspirin in conjunction with
he underlying or basal platelet function, which is itself
ighly variable and correlated with clinical outcomes. Ade-
uately powered clinical trials, with platelet function mea-
ured before and after the initiation of antiplatelet therapy,
re still needed because the correlations between the differ-
nces in platelet response and clinical outcomes are what
ill permit bona fide inferences about the effects of aspirin.
t will then be crucial to understand whether an alternate
ntiplatelet therapy (e.g., high-dose aspirin, clopidogrel, or
ombination therapy) improves platelet suppression and
linical outcome among those who are otherwise “nonre-
ponders.” At present, there is no quantitative measure of
he effect of aspirin that can reliably predict the drug’s ability
o prevent ischemic vascular events.
What insights can be gleaned from the two studies
11,12) in this issue of the Journal? Both studies were
elatively small (82 and 49 subjects) and focused on patients
nown to be acutely dependent on adequate antiplatelet
rotection: patients undergoing coronary stent placement.
ach study retrospectively identified patients with stent
hrombosis and determined their platelet responsiveness
ither to shear or to chemical agonists. Similar to previous
tudies, both reported differences in platelet responsiveness
mong patients who had experienced stent thrombosis as
ompared with a matched historical control group. Unfor-
unately, but clinically appropriate, neither study deter-
ined platelet function in patients free of all antiplatelet
herapy. In the study by Ajzenberg et al. (11), the difference
n platelet response between the groups is likely partially
xplained by the close proximity (mean, 4.6 days) of platelet
esting after the index thrombotic event. As such, the
ncrease in shear-induced platelet aggregation detected
ould represent an effect of the stent thrombosis rather than
cause. In the study by Wenaweser et al. (12), greater
denosine diphosphate-induced platelet aggregation was
bserved among patients treated with aspirin who had
xperienced stent thrombosis compared with control sub-
ects, but no significant difference was found when patients
ere given aspirin and clopidogrel. Although the authors
oncluded that impaired responsiveness to aspirin may be
ssociated with stent thrombosis, it is more likely that
denosine diphosphate-induced aggregation in the patients
reated with aspirin is more a measure of intrinsic platelet
unction and less a measure of the effects of aspirin.
Where do these data leave us? Considering Figure 2 in
he paper by Wenaweser et al. (12), one can see the
ensitivity and specificity of aspirin resistance for predicting
tent thrombosis in this study to be 48% and 68%, respec-
ively. This result might seem a reasonable start, but if wessume that the incidence of stent thrombosis is 0.5% to 2%,
he corresponding positive predictive value (between 0.7%
nd 3.0%) is dismal, signaling the need for better diagnos-
ics. Likewise, a challenge inherent to these and nearly all
etrospective studies is both the uncertainty of the true
isease incidence and the inability to assess all identified
ffected individuals. This arena is strikingly reminiscent of
revious studies and views of heparin-induced thrombocy-
openia. Despite these many limitations and caveats and
egardless of where we now stand, as a next step forward, we
eed to stop resisting the concept of aspirin and clopidogrel
esistance and systematically move forward—next month’s
apers will soon be here.
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00 South Limestone Street, 326 Charles T. Wethington Build-
ng, Lexington, Kentucky 40536-0200. E-mail: steinhubl@
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